CSIMarket
 
Curis Inc   (CRIS)
Other Ticker:  
 
 
Price: $10.3000 $0.11 1.079%
Day's High: $10.36 Week Perf: -0.48 %
Day's Low: $ 10.07 30 Day Perf: 0.1 %
Volume (M): 11 52 Wk High: $ 15.11
Volume (M$): $ 116 52 Wk Avg: $4.66
Open: $10.18 52 Wk Low: $0.38



 Market Capitalization (Millions $) 996
 Shares Outstanding (Millions) 97
 Employees -
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -47
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Curis Inc
Curis Inc is a biotechnology company that focusses on developing innovative cancer therapies. Founded in 2000, the company is headquartered in Lexington, Massachusetts. Curis has a strategic collaboration with Aurigene and is known for its expertise in precision medicine and small molecule drug development.

The company's primary goal is to discover and develop novel targeted therapies for the treatment of various cancers. They utilize a proprietary drug discovery platform to identify potential drug candidates, focusing on signaling pathways and targeted proteins that play crucial roles in tumor growth and survival.

Curis has several drug candidates in its pipeline, with some in various stages of clinical development. Their lead candidate, CUDC-907, is being evaluated for the treatment of hematological cancers such as lymphoma. The company also has collaborations with other pharmaceutical companies to advance the development of their drug candidates.

Curis has a dedicated team of scientists and researchers who work towards translating scientific discoveries into potential cancer treatments. The company aims to bring innovative therapies to patients and improve outcomes in oncology.

In summary, Curis Inc is a biotechnology company that specializes in the development of targeted cancer therapies. With a focus on precision medicine and small molecule drug development, the company aims to make a significant impact in the field of oncology.


   Company Address: 128 Spring Street, Building C - Suite 500 Lexington 2421 MA
   Company Phone Number: 503-6500   Stock Exchange / Ticker: NASDAQ CRIS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Curis Inc

Curis Inc's fiscal period ends on a challenging note, with mixed performance and concerning trends in Q4 2023 earnings

Financial results for Curis Inc for the fiscal time-frame ending December 31, 2023, reveal mixed performance with some concerning trends. The company saw a widening of diminishing returns, with a loss per share of $-0.12 compared to $-0.11 in the previous year. However, earnings per share improved from $-2.13 to $-8.96 per share.
Revenue also took a hit, depreciating by -6.616% to $2.70 million, down from $2.89 million in the same period a year prior. Sequentially, revenue decreased by -4.836% from $2.83 million. This contrasts with the performance of the Biotechnology & Pharmaceuticals industry as a whole, which saw a revenue growth of 9.84% in the fourth quarter of 2023 compared to the previous year.

Curis Inc

Curis Inc.: Deficit Soars to $-2.13 per Share, Mirrors Intensifying Losses in Latest Fiscal Period

Curis Inc, a biotechnology and pharmaceutical company, recently released its latest fiscal report, revealing mixed results for the most recent period. The company reported a significant increase in its deficit per share, reaching $-2.13 per share compared to $-0.14 in the previous year's fiscal period. Additionally, the deficit advanced from $-0.12 per share from the preceding financial reporting period.
Despite the negative news about the deficit, Curis Inc did experience some positive growth in its revenue. The company saw a slight increase of 0.283% in revenue, reaching $2.83 million from $2.83 million in the corresponding financial reporting period a year prior. Moreover, the revenue improved sequentially by 28.949% from $2.20 million.

Curis Inc

Curis Inc Suffers Revenue Dip and Share Decrease Amidst Falling Orders for Q2 2023



Curis Inc, a prominent player in the Biotechnology & Pharmaceuticals sector, recently released its financial results for the April to June 30, 2023 period. The report highlights a decline in revenue, lower orders, and increased shortfall compared to the previous year. This article will analyze these outcomes and explore the potential impacts they might have on the company's future prospects.
Revenue Decline and Lower Orders:
During the reported period, Curis Inc witnessed a significant decline in revenue. The figures dropped by 8.191% to $2.20 million, compared to the previous year's revenue of $2.30 million. This decline can be attributed to lower orders, which resulted in diminishing revenue streams. The main concern for the company is the inability to maintain stable revenue growth, especially when compared to the overall improvement seen in the Biotechnology & Pharmaceuticals sector.

Curis Inc

Biotech Leader Curis Inc. Shatters Revenue Expectations with Astonishing Q1 2023 Surge

Curis Inc, a clinical-stage biotechnology company, recently reported its financial performance for the first quarter of the fiscal year 2023, ending on March 31st. According to the company's financial report, Curis recorded revenue of $2.30 million, which represented an 11.667% increase from the same period of the previous year. Despite the positive revenue growth, the company's net deficit per share stood at $-0.12, indicating that Curis ended the quarter in the red.
Comparing the latest revenue and deficit figures to the previous quarter, Curis recorded a decline of -20.436% from revenue of $2.89 million. Moreover, the advanced deficit increased from $-0.11 per share. These numbers suggest that while the company's revenue growth may have been positive compared to previous years, it was not consistent over the last few quarters.






 

Curis Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Curis Inc does not provide revenue guidance.

Earnings Outlook
Curis Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com